The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients

摘要: Despite the progress of therapy, outcomes advanced hepatoblastoma patients who are refractory to standard preoperative chemotherapy remain unsatisfactory. To improve mortality rate, novel prognostic markers needed for better therapy planning. We examined methylation status 13 candidate tumor suppressor genes in 20 tumors by conventional methylation-specific PCR (MSP) and found hypermethylation 3 genes. analyzed these (RASSF1A, SOCS1 CASP8) 97 30.9, 33.0 15.5%, respectively. Univariate analysis showed that only RASSF1A but not other 2 predicted outcome, multivariate a weak contribution overall survival. Using quantitative MSP, we 44.3% tumors. CTNNB1 mutation was detected 67.0% While univariate demonstrated methylation, clinicopathological variables as factors, identified (p = 0.043; relative risk 9.39) disease stage 0.002; 7.67) independent factors. In survival 33 3B or 4, with unmethylated had than those methylated 0.035). may be promising molecular-genetic marker predict treatment outcome used stratify when clinical trials carried out.